Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.53 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.50 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798417 | 1.00 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2936924 | 1.00 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2197651 | 1.00 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL491107 | 1.00 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| SCHEMBL2197644 | 1.00 | KDM1A (0.58) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL17822680 | 0.98 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL16799767 | 0.98 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL18129441 | 0.98 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Ammonia Solution, Strong SCHEMBL2987109 | 0.98 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 | |
| Bromide SCHEMBL17822672 | 0.98 | KDM1A (0.56) | KDM1AMAOAGRIN2BFUCA1SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| EP-2398769-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | BRACCO IMAGING S.P.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| WO-2010094678-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100069628-A1 | Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy | BRACCO IMAGING S.P.A (IT) | 2010-03-18 | — | — | US | disclosed |
| EP-0558656-B1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INST TECHNOLOGY (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0558656-A1 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES. | MASSACHUSETTS INST TECHNOLOGY (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1992009545-A2 | NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | CD99, CD209, PRMT9 | KDM1A 2429/4885MAOA 376/4885GRIN2B 457/4885 |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | KDM1A 57/4885MAOA 1064/4885GRIN2B 1272/4885 |
| US-20100069628-A1 | Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy | CD99, MB, HBZ | KDM1A 2458/4885MAOA 615/4885GRIN2B 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.